At a Glance
| Indication | Symptomatic dermographism |
| Drug | remibrutinib |
| Mechanism of Action | Bruton’s tyrosine kinase inhibitor (BTKi) |
| Company | Novartis |
| Trial Phase | Phase III |
| Trial Acronym | RemIND |
| Category | Regulatory Milestone |
| Sub Category | Approval Granted |
| Therapeutic Area | Immunology |
| Regulatory Agency | FDA |
| Approved Market/Region | U.S. |
| Approval Date | October 7, 2026 |
| Patient Population | Adults with symptomatic dermographism inadequately controlled by H1 antihistamines |
| Comparator | Placebo |
| Primary Endpoint Measure | Total Fric Score |
| Complete Response Rate (Drug) | 29.3% |
| Complete Response Rate (Placebo) | 14.0% |
| P-value | 0.0229 |
| Other Approved Indication | Chronic spontaneous urticaria (CSU) |
| Other Investigated Indications | Cold urticaria (ColdU), Cholinergic urticaria (CholU), Hidradenitis suppurativa (HS), Food allergy, Relapsing multiple sclerosis (RMS) |
FDA Approves Novartis' Rhapsido for Symptomatic Dermographism
Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. This approval is based on data from the Phase III RemIND trial, where twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 compared to placebo. The drug demonstrated a safety profile consistent with chronic spontaneous urticaria (CSU), requiring no routine lab monitoring. This expands Rhapsido's utility, making it the only prescription treatment approved for both CSU and SD.
- The FDA approval is supported by efficacy data from the SD cohort of the Phase III RemIND clinical trial. At Week 12, 29.3% of patients treated with Rhapsido achieved complete response from hives, significantly higher than the 14.0% in the placebo group (p=0.0229), with responses observed as early as Week 2. Efficacy was measured by the Total Fric Score.
- Rhapsido demonstrated a consistent safety profile in both SD and CSU clinical trials up to Week 24, with no routine lab monitoring required. The most frequently reported adverse events (incidence ≥3%) included nasopharyngitis (nasal congestion, sore throat, runny nose), bleeding, headache, nausea, and abdominal pain.
- This approval marks Rhapsido as the first FDA-approved treatment specifically for symptomatic dermographism, addressing a significant unmet need for patients whose chronic hives and itch are triggered by skin friction and are not adequately controlled by H1 antihistamines. It also establishes Rhapsido as the only treatment indicated for the two most common forms of chronic hives: CSU and SD.
Frequently Asked Questions
What autoimmune disease is linked to dermatographia?
Dermatographia, a form of inducible urticaria, is not an autoimmune disease itself but can be associated with underlying autoimmune conditions. The most frequently reported autoimmune link is with thyroid disorders, particularly autoimmune thyroiditis such as Hashimoto's disease. While less common, dermatographia has also been observed in patients with other autoimmune conditions, including systemic lupus erythematosus and Sjögren's syndrome, suggesting a potential broader immune dysregulation in some cases.
Does dermatographia mean you have MCAS?
Dermatographia is a common form of physical urticaria, affecting 2-5% of the population, and is not pathognomonic for Mast Cell Activation Syndrome (MCAS). While it can be a symptom, an MCAS diagnosis requires recurrent multi-systemic symptoms and evidence of mast cell mediator release, fulfilling established diagnostic criteria beyond dermatographia alone.
What causes symptomatic dermatographia?
Symptomatic dermatographia is a form of physical urticaria resulting from an exaggerated localized mast cell degranulation in response to mechanical pressure or stroking of the skin. This degranulation releases histamine and other inflammatory mediators, leading to the characteristic wheal-and-flare reaction, pruritus, and erythema. While often idiopathic, its onset or exacerbation can be associated with stress, infections, certain medications, or underlying systemic conditions.
Will dermographism ever go away?
Dermographism, a common form of chronic inducible urticaria, often resolves spontaneously, though its duration is highly variable. While it can persist for months to many years, it is not universally a lifelong condition. For many individuals, the condition eventually remits, though the exact timeline is unpredictable. Management primarily involves antihistamines to control symptoms.
How can symptomatic dermographism be treated?
Symptomatic dermographism is primarily managed with non-sedating H1-antihistamines, often taken daily to prevent symptom onset. For refractory cases, increasing the H1-antihistamine dose up to four-fold, or adding H2-antihistamines or leukotriene receptor antagonists, may be considered. Omalizumab is an option for patients unresponsive to high-dose antihistamines, particularly when dermographism is part of chronic inducible urticaria. Non-pharmacological strategies include avoiding physical triggers such as tight clothing, friction, and hot showers.
How common is symptomatic dermographism?
Symptomatic dermographism is the most common form of chronic inducible urticaria. It affects an estimated 2-5% of the general population, though some studies report prevalence figures as high as 7%. This makes it a relatively common dermatological condition encountered in clinical practice.
How to stop a dermatographia flare up?
Acute dermatographia flare-ups are primarily managed with H1 antihistamines, which block histamine release responsible for the characteristic wheal and flare reactions. Non-sedating second-generation antihistamines like cetirizine or loratadine are typically recommended, with dose escalation often necessary for symptom control in refractory cases. While avoiding physical triggers is crucial, severe, chronic cases unresponsive to high-dose antihistamines may warrant consideration of omalizumab.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
